Please assess the completion status of the following clinical trial:

Trial Title: HCT Versus CT in Elderly AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60years and ≤ 75 years~* primary or secondary AML as defined by WHO or refractory anemia with excess of blasts (RAEB)~* First complete remission following one or two cycles of induction chemotherapy~* Chemotherapy was administered according to current participating cooperative group protocols~* Karnofsky score ≥ 70~* Written informed consent~Exclusion Criteria:~* AML FAB M3~* HIV positivity~* Participation in another clinical trial without prior consent of the coordinating investigator, patients may exceptionally take part in a further study only if~  * The second study exclusively concerns induction therapy~ * Consolidation cycle one and two are given according to the accredited study group policy~ * No investigational drugs are used post registration for the HCT vs CT in eldery AML study.~ * Documentation for the HCT vs CT in eldery AML study is not compromised. Second hand data from foreign study is not accepted

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Arm (Type: EXPERIMENTAL): Hematopoietic cell transplantation after Reduced Intensity Conditioning
- Conventional Chemotherapy (Type: ACTIVE_COMPARATOR): The non-transplant treatment approach for consolidation

Based on this trial design, predict the completion outcome and termination type (if applicable).